G G Illei

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus
    Larissa Lapteva
    Sjögren s Syndrome Clinic, National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland 20892, USA
    Arthritis Rheum 54:2505-14. 2006
  2. ncbi Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis
    G G Illei
    National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
    Rheumatology (Oxford) 46:952-6. 2007
  3. ncbi Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus
    Yuko Shirota
    Correspondence to Dr Gabor G Illei, Sjögren s Syndrome Clinic, National Institute of Dental and Craniofacial Research, National Institutes of Health, 10 Center Drive, Room 1N 110, Bethesda, Maryland 20892, USA
    Ann Rheum Dis 72:118-28. 2013
  4. ncbi Biomarkers in systemic lupus erythematosus: II. Markers of disease activity
    Gabor G Illei
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, DHHS, Bethesda, Maryland 20892, USA
    Arthritis Rheum 50:2048-65. 2004
  5. ncbi Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
    Gabor G Illei
    National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA
    Arthritis Rheum 62:542-52. 2010
  6. ncbi Novel approaches in the treatment of lupus nephritis
    G G Illei
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 9S205, Bethesda, MD 20892, USA
    Expert Opin Investig Drugs 10:1117-30. 2001
  7. ncbi Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus
    Gabor G Illei
    National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Rheum Dis 70:2071-4. 2011
  8. ncbi Blood stem cells as therapy for severe lupus
    Gabor G Illei
    National Institute of Dental and Craniofacial Research, Sjögren s Syndrome Clinic, 9000 Rockville Pike, Bethesda, MD 20892 1190, USA
    Expert Opin Biol Ther 5:1153-64. 2005
  9. ncbi Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases
    G G Illei
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Building 10, Bethesda, MD 20892, USA
    Curr Opin Immunol 12:712-8. 2000
  10. ncbi Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability
    Gabor G Illei
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Arthritis Rheum 50:1709-20. 2004

Detail Information

Publications56

  1. ncbi Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus
    Larissa Lapteva
    Sjögren s Syndrome Clinic, National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland 20892, USA
    Arthritis Rheum 54:2505-14. 2006
    ..To assess the association of cognitive dysfunction and depression with serum antibodies to N-methyl-D-aspartate (NMDA) receptor (anti-NR2) and analyze clinical and neuroimaging correlates in patients with systemic lupus erythematosus (SLE)...
  2. ncbi Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis
    G G Illei
    National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
    Rheumatology (Oxford) 46:952-6. 2007
    ..To determine the safety and efficacy of a short course of fludarabine combined with cyclophoshamide in lupus nephritis...
  3. ncbi Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus
    Yuko Shirota
    Correspondence to Dr Gabor G Illei, Sjögren s Syndrome Clinic, National Institute of Dental and Craniofacial Research, National Institutes of Health, 10 Center Drive, Room 1N 110, Bethesda, Maryland 20892, USA
    Ann Rheum Dis 72:118-28. 2013
    ..Circulating plasmablasts/plasma cells and activated B and T cells are increased in systemic lupus erythematosus (SLE). Interleukin (IL)-6 induces differentiation of B cells into antibody-forming cells and of T cells into effector cells...
  4. ncbi Biomarkers in systemic lupus erythematosus: II. Markers of disease activity
    Gabor G Illei
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, DHHS, Bethesda, Maryland 20892, USA
    Arthritis Rheum 50:2048-65. 2004
  5. ncbi Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
    Gabor G Illei
    National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA
    Arthritis Rheum 62:542-52. 2010
    ..To assess the safety of interleukin-6 receptor inhibition and to collect preliminary data on the clinical and immunologic efficacy of tocilizumab in patients with systemic lupus erythematosus (SLE)...
  6. ncbi Novel approaches in the treatment of lupus nephritis
    G G Illei
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Building 10, Rm 9S205, Bethesda, MD 20892, USA
    Expert Opin Investig Drugs 10:1117-30. 2001
    ....
  7. ncbi Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus
    Gabor G Illei
    National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Rheum Dis 70:2071-4. 2011
    ..Development of stronger transplant registries, defining a core set of clinical data and standardising biological sample collections would make future collaborations and comparison of studies more feasible...
  8. ncbi Blood stem cells as therapy for severe lupus
    Gabor G Illei
    National Institute of Dental and Craniofacial Research, Sjögren s Syndrome Clinic, 9000 Rockville Pike, Bethesda, MD 20892 1190, USA
    Expert Opin Biol Ther 5:1153-64. 2005
    ..All immunoablative protocols should incorporate studies of immune reconstitution to understand the mechanisms of cure or failure...
  9. ncbi Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases
    G G Illei
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Building 10, Bethesda, MD 20892, USA
    Curr Opin Immunol 12:712-8. 2000
    ..Moreover, the progression of joint damage noted in patients with rheumatoid arthritis treated with methotrexate was prevented by an anti-TNF-alpha antibody, suggesting a genuine disease-modifying potential of TNF-alpha blockade...
  10. ncbi Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability
    Gabor G Illei
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Arthritis Rheum 50:1709-20. 2004
  11. ncbi Biomarkers in systemic lupus erythematosus
    Gabor G Illei
    National Institutes of Health, Department of Health and Human Services, 10 Center Drive, Room 9S205, Bethesda, MD 20892, USA
    Curr Rheumatol Rep 6:382-90. 2004
    ..We also report on the current status of a multicenter initiative to concentrate efforts of biomarker development...
  12. ncbi Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis
    G G Illei
    Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 10 Center Drive, Building 10, Room 9S 205, Bethesda, MD 20892, USA
    Ann Intern Med 135:248-57. 2001
    ..The long-term effectiveness and side-effect profiles of pulse immunosuppressive regimens warrant further study...
  13. ncbi CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms
    T Kuroiwa
    Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20892, USA
    J Immunol 163:2168-75. 1999
    ....
  14. ncbi IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis
    I B McInnes
    Arthritis and Rheumatism Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 167:4075-82. 2001
    ..Such biological changes may result in clinically meaningful improvement in disease activity...
  15. ncbi Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects
    K Takada
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Ann Rheum Dis 62:1112-5. 2003
    ..To obtain preliminary information on the safety and efficacy of fludarabine in PsA and analyse its immunomodulatory effects in peripheral blood and synovial tissue...
  16. ncbi Distinct T cell/renal tubular epithelial cell interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritides
    T Kuroiwa
    Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 164:3323-9. 2000
    ..Recognition of this regulatory diversity has important implications in the choice of potential therapeutic targets in GN...
  17. ncbi Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome
    N Roescher
    Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
    Oral Dis 18:96-106. 2012
    ..Non-obese diabetic (NOD) mice develop an autoimmune exocrinopathy that shows similarities with Sjögren's syndrome. They provide an experimental model to study the pathoetiogenesis of this disease...
  18. ncbi Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies
    G G Illei
    Arthritis and Rheumatism Branch, NIAMS, NIH, Bethesda, Maryland 20892, USA
    Arthritis Rheum 46:995-1002. 2002
    ..We reviewed the cases of renal flares in a cohort of patients who participated in 2 randomized controlled clinical trials at the National Institutes of Health and explored the prevalence, outcome, and predictive factors of renal flares...
  19. ncbi Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis
    G M Kuo
    Department of Pharmacy, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 21:528-33. 2001
    ..CONCLUSION: Subcutaneous and intravenous administration of fludarabine appear to have similar pharmacokinetics in patients with lupus nephritis. Subcutaneous injection may offer a convenient alternative to intravenous administration...
  20. ncbi Cyclophosphamide for the treatment of systemic lupus erythematosus
    K Takada
    Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Lupus 10:154-61. 2001
    ....
  21. ncbi Biologic treatments for systemic rheumatic diseases
    Y Shirota
    Sjögren s Syndrome Clinic, Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
    Oral Dis 14:206-16. 2008
    ..In this review, we will summarize the current state of biologic therapies in rheumatology and discuss the implications of these on oral health and disease...
  22. ncbi Abnormal differentiation of memory T cells in systemic lupus erythematosus
    Ruth D Fritsch
    NIAMS, NIH, Building 10, Room 6D47C, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Arthritis Rheum 54:2184-97. 2006
    ..The goal of this study was to examine maturational disturbances in CD4 T cell differentiation in systemic lupus erythematosus (SLE), using these phenotypic markers...
  23. ncbi Deep sequencing of short RNAs reveals novel microRNAs in minor salivary glands of patients with Sjögren's syndrome
    M Tandon
    Sjögren s Syndrome Clinic, Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA
    Oral Dis 18:127-31. 2012
    ..We use ultradeep sequencing of small RNAs from patients with Sjögren's syndrome and healthy volunteers, primarily to identify and discover novel miRNA sequences that may play a role in the disease...
  24. ncbi Exosomes from human saliva as a source of microRNA biomarkers
    A Michael
    Sjögren s Syndrome Clinic, Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, Bethesda, MD 20892, USA
    Oral Dis 16:34-8. 2010
    ..The aim of this study was to examine the presence of microRNAs (miRNAs) within exosomes isolated from human saliva and to optimize and test methods for successful downstream applications...
  25. ncbi Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome
    Peter D Burbelo
    Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
    Autoimmunity 42:515-24. 2009
    ..These heterogeneous autoantibody responses detected by LIPS in SjS will likely be useful for diagnosis and for evaluating extraglandular manifestations...
  26. ncbi Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures
    Dat Q Tran
    Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 113:5125-33. 2009
    ..This novel protocol should facilitate the purification of Tregs for both cell-based therapies as well as detailed studies of human Treg function in health and disease...
  27. ncbi Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy
    Howard A Austin
    Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, CRC 5 2551, Bethesda, Maryland 20892 1455, USA
    J Am Soc Nephrol 20:901-11. 2009
    ..In conclusion, regimens containing CsA or IVCY are each more effective than prednisone alone in inducing remission of proteinuria among patients with LMN...
  28. ncbi Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892 1886, USA
    Blood 103:3986-8. 2004
    ..This finding implies that overrepresentation of CD4(EM) cells is a unique feature of cGVHD...
  29. ncbi Development of a gene transfer-based treatment for radiation-induced salivary hypofunction
    Bruce J Baum
    National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
    Oral Oncol 46:4-8. 2010
    ..A Phase I/II clinical trial, using a recombinant adenoviral vector to mediate gene transfer, is currently underway...
  30. ncbi Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions
    Amrie C Grammer
    Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 112:1506-20. 2003
    ....
  31. ncbi Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus
    Susan F Leitman
    Department of Transfusion Medicine, National Institute of Muscuoloskeletal and Skin Disease, National Institute of Health, Bethesda, MD 20892, USA
    Transfusion 43:1667-71. 2003
    ..Its role as a risk factor for TA-GVHD in patients without underlying leukemia or lymphoma is uncertain...
  32. ncbi Cytokines in Sjogren's syndrome: potential therapeutic targets
    Nienke Roescher
    Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, 10 Center Drive, Bethesda, MD 20892 1190, USA
    Ann Rheum Dis 69:945-8. 2010
    ..Additionally, as an alternative to systemic treatment, which has the risk of potentially severe side effects, the use of local cytokine directed therapy should be explored...
  33. ncbi Identification and characterization of circulating human transitional B cells
    Gary P Sims
    Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health, Bethesda, MD, USA
    Blood 105:4390-8. 2005
    ..Notably, increased proportions of T1 B cells were found in blood of patients with systemic lupus erythematosus (SLE), although bone marrow production and selection appeared to be normal...
  34. ncbi Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction
    Bruce J Baum
    Gene Therapy and Therapeutics Branch, Bethesda, MD 20892 1190, USA
    Biochim Biophys Acta 1758:1071-7. 2006
    ..Based on these results, we are developing a clinical trial to test if the hAQP1 cDNA transfer strategy will be clinically effective in restoring salivary flow in patients with IR-induced parotid hypofunction...
  35. ncbi Rationale for interleukin-6 blockade in systemic lupus erythematosus
    E Tackey
    Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA
    Lupus 13:339-43. 2004
    ..Based on these data, we propose that blocking the effect of IL-6 in humans may improve lupus by interacting with the autoinflammatory process both systemically and locally...
  36. ncbi Membranous lupus nephritis
    H A Austin
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-1190, USA
    Lupus 14:65-71. 2005
    ..Prospective controlled trials are clearly needed in order to establish solid clinical practice guidelines for use of these drugs and other experimental therapies currently under study in membranous lupus nephropathy...
  37. ncbi Basophils and the T helper 2 environment can promote the development of lupus nephritis
    Nicolas Charles
    Laboratory of Molecular Immunogenetics, National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS, National Institutes of Health NIH, Bethesda, Maryland, USA
    Nat Med 16:701-7. 2010
    ....
  38. ncbi Effect of serotype 5 adenoviral and serotype 2 adeno- associated viral vector-mediated gene transfer to salivary glands on the composition of saliva
    Jianghua Wang
    Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, Bethesda, MD 20892-1190, USA
    Hum Gene Ther 17:455-63. 2006
    ....
  39. ncbi A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
    Dimitrios T Boumpas
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Arthritis Rheum 48:719-27. 2003
    ..The primary outcome measure was 50% reduction in proteinuria without worsening of renal function...
  40. ncbi Peptide-based ELISAs are not sensitive and specific enough to detect muscarinic receptor type 3 autoantibodies in serum from patients with Sjogren's syndrome
    N Roescher
    Correspondence to Nienke Roescher, NIH NIDCR MPTB, 10 Center Drive, Building 10, Room 1A21, Bethesda, MD 20892 1190, USA
    Ann Rheum Dis 70:235-6. 2011
    ..A study was undertaken to test whether modification of M3R peptides could enhance the antigenicity and increase the detection of specific antibodies using an ELISA...
  41. ncbi Helicobacter pylori and autoimmune diseases
    S Hasni
    National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health, Bethesda, MD 20892, USA
    Oral Dis 17:621-7. 2011
    ..pylori might contribute to the development of autoimmune diseases. In this article, we review the available literature regarding the role of chronic H. pylori infection in various autoimmune disease states...
  42. ncbi Cytokines in Sjögren's syndrome
    N Roescher
    Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
    Oral Dis 15:519-26. 2009
    ....
  43. ncbi Apheresis
    G G Illei
    Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Rheum Dis Clin North Am 26:63-73, viii. 2000
    ..Although numerous case reports describe clinical benefits of apheresis in rheumatologic disorders, data from clinical trials are discouraging and suggest a limited role for apheresis in rheumatic disease management...
  44. ncbi The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus
    G Oroszi
    Laboratory of Neurogenetics, National Institute of Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA
    Ann Rheum Dis 65:1330-5. 2006
    ..As cognitive function is commonly impaired in patients with systemic lupus erythematosus (SLE), the association of the BDNF Val66Met with neurocognitive function was studied...
  45. ncbi Monocyte response to Th1 stimulation and effector function toward human mesangial cells are not impaired in patients with lupus nephritis
    Takashi Kuroiwa
    Arthritis and Rheumatism Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Immunol 106:65-72. 2003
    ..Thus, in contrast to earlier reports, Th1-dependent monocyte activation is not impaired. In this disease activated monocytes appear to be fully capable of inducing renal injury...
  46. ncbi Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis
    Kazuki Takada
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892, USA
    Arthritis Rheum 50:2202-10. 2004
    ..We conducted a retrospective cohort study to test whether genetic polymorphisms of these enzymes are associated with the toxicity of, and clinical response to, cyclophosphamide in patients with lupus nephritis...
  47. ncbi Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland
    Changyu Zheng
    Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892 1190, USA
    J Gene Med 12:3-10. 2010
    ..One week after the administration of AdhAQP1 to an enrolled, generally healthy patient, E1-containing adenovirus was detected in parotid saliva...
  48. ncbi The role of immune ablation and stem cell transplantation in severe SLE
    Steven Z Pavletic
    Graft-Versus-Host and Autoimmunity Unit, Experimental Transplantation and Autoimmunity Branch, National Cancer Institute, Bethesda, MD, USA
    Best Pract Res Clin Rheumatol 19:839-58. 2005
    ..All immunoablative protocols should incorporate carefully planned studies of immune reconstitution to understand the mechanisms of cure or failure...
  49. ncbi Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis
    O H Ryu
    Human Craniofacial Genetics Section, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research (NIDCR, National Institutes of Health (NIH, Bethesda, MD 20892-1470, USA
    Rheumatology (Oxford) 45:1077-86. 2006
    ..Future studies will test the ability of these biomarker levels, alone and in combination, to diagnose the salivary component of SS...
  50. ncbi Variant form of STAT4 is associated with primary Sjögren's syndrome
    B D Korman
    Complex Disease Genetics Unit, Genetics and Genomics Branch, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, Bethesda, MD 20892, USA
    Genes Immun 9:267-70. 2008
    ..6%) than in controls (22.3%), leading to a P-value for association of 0.01. These results implicate polymorphisms in the STAT4 gene in the pathogenesis of pSS...
  51. ncbi A pilot study of the use of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus
    Miroslawa Nowak
    National Institute of Arthritis and Musculoskeletal Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Arthritis Rheum 50:1233-8. 2004
    ..The increased thymic uptake observed only in patients with active disease suggests that the thymus plays an important role during periods of disease activity...
  52. ncbi Urinary exosomal transcription factors, a new class of biomarkers for renal disease
    Hua Zhou
    Renal Diagnostics and Therapeutics Unit, National Institutes of Health, Bethesda, Maryland, USA
    Kidney Int 74:613-21. 2008
    ..Measurement of urinary exosomal transcription factors may offer insight into cellular regulatory pathways...
  53. ncbi Diagnosis and treatment of vasculitis of the central nervous system in a patient with systemic lupus erythematosus
    Nikolay P Nikolov
    National Institute of Dental and Craniofacial Research, Gene Therapy and Therapeutics Branch, NIH, Bethesda, MD 20892, USA
    Nat Clin Pract Rheumatol 2:627-33; quiz 634. 2006
    ..Prednisone was tapered over 18 months. Cyclophosphamide was discontinued after 2 years because of poor bone-marrow tolerance, and was replaced with mycophenolate mofetil 3,000 mg/ day and ciclosporin 50 mg twice daily...
  54. ncbi MicroRNAs as biomarkers in rheumatic diseases
    Ilias Alevizos
    Sjögren s Syndrome Clinic, Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, 10 Center Drive, 1N110, Bethesda, MD 20892, USA
    Nat Rev Rheumatol 6:391-8. 2010
    ..MiRNAs identified as potential biomarkers in pilot studies should be validated in larger studies designed specifically for biomarker validation...
  55. ncbi Pathogenesis of Sjögren's syndrome
    Nikolay P Nikolov
    Sjögren s Syndrome Clinic, National Institute of Dental and Craniofacial Research NIDCR, Molecular Physiology and Therapeutics Branch, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    Curr Opin Rheumatol 21:465-70. 2009
    ..To summarize recent developments in our understanding of the pathogenesis of Sjögren's syndrome with a focus on the relationship between inflammation and exocrine dysfunction...
  56. ncbi Hematopoietic stem cell transplantation in autoimmune diseases: is the glass half full or half empty?
    Gabor G Illei
    Arthritis Rheum 54:3730-4. 2006